Fundraising Fox
/Companies
Sign in

Synedgen

Claremont, US · Founded 2009 · Delaware corporation

Find your way into Synedgen

Sign up to see every warm intro you have to Synedgen

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Synedgen team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Synedgen develops first-in-class glycomics-based regenerative therapeutics that repair mucosal injury and restore barrier function. Its lead asset, MIIST305, is an orally delivered therapeutic that repairs gastrointestinal mucosal injury and reduces inflammation.

BiotechHealthtech

Founders & leadership

Synedgen was founded in 2009 by Shenda Baker and William P. Wiesmann.

SBShenda Baker
Shenda BakerCo-founder · President and CEO2019–2025
WP
William P. WiesmannCo-founder · CEO and Chairman
KP
Kaveri ParkerChief Business Officer2018–2025
LSLaura Saward
Laura SawardChief Executive OfficerLaura Saward held leadership positions including Chief Scientific Officer and Senior Vice President at a pharmaceutical organization, where she oversaw R&D operations for 30+ programs in infectious disease, rare disease, and biodefense, and led accelerated clinical development of COVID-19 therapeutics. She is now Chief Executive Officer of Synedgen, which develops glycomics-based regenerative therapeutics for mucosal injury repair.

Board

PC
Paul C. GrintBoard director
HO
Hal OienBoard director
AW
Andrew W. MillerBoard director
DBDaniel Bradbury
Daniel BradburyDirector2019–2024Investor at BioBrit
KG
Kenton GregoryChief Medical Officer
CA
Clarke AtwellBoard director
LS
Larry ShapiroBoard director
DO
Diane OlmsteadBoard director

Reported raises · per SEC filings

Form D private placements

$20.4M disclosed across 7 rounds · 2014–2024

▶$1.8MraisedOct 2024 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shenda BakerExecutive Officer, Director
  • William P. WiesmannExecutive Officer, Director
  • Paul C. GrintDirector
  • Hal OienDirector
  • Andrew W. MillerDirector
  • Daniel BradburyDirector
  • Kaveri ParkerExecutive Officer
  • Kenton GregoryDirector
Offering amount
$2M
Amount sold
$1.8M
Proceeds to insiders
$465K
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedJul 2019 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shenda BakerExecutive Officer, Director
  • William P. Wiesmann, M.D.Executive Officer, Director
  • Kenton Gregory, M.D.Director
  • Paul Grint, M.D.Director
  • Andrew W. MillerDirector
Offering amount
$3M
Amount sold
$2.5M
First sale
Jun 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedSep 2017 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Kenton Gregory, M.D.Director
  • Shenda BakerExecutive Officer, Director
  • William P. Wiesmann, M.D.Executive Officer, Director
  • Robert CoughlinDirector
  • Andrew W. MillerDirector
  • Paul Grint, M.D.Director
Offering amount
$3M
Amount sold
$3M
First sale
Aug 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedNov 2016 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Kenton GregoryDirector
  • Paul GrintDirector
  • Robert CoughlinDirector
  • William WeismannExecutive Officer, Director
  • Larry ShapiroDirector
  • Andrew MillerDirector
  • Shenda BakerExecutive Officer, Director
Offering amount
$3.5M
Amount sold
$3M
First sale
Oct 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedApr 2016 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul GrintDirector
  • Shenda BakerExecutive Officer, Director
  • Kenton GregoryDirector
  • Larry ShapiroDirector
  • Clarke AtwellDirector
  • Diane OlmsteadDirector
  • Andrew MillerDirector
  • William WiesmannExecutive Officer, Director
Offering amount
$6.5M
Amount sold
$6M
First sale
Apr 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.5MraisedMar 2015 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Clarke AtwellDirector
  • Larry ShapiroDirector
  • William WiesmannExecutive Officer, Director
  • Kenton GregoryDirector
  • Diane OlmsteadDirector
  • Andrew MillerDirector
  • Shenda BakerExecutive Officer, Director
Offering amount
$4M
Amount sold
$3.5M
First sale
Feb 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$607.4KraisedAug 2014 · 15 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Clarke AtwellDirector
  • Andrew W. MillerDirector
  • Shenda BakerExecutive Officer, Director
  • Kenton GregoryDirector
  • Larry ShapiroDirector
  • Diane OlmsteadDirector
Offering amount
$607.4K
Amount sold
$607.4K
First sale
Aug 2014
Incorporated
Corporation, Delaware, 2009
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Synedgen went on to found or lead other companies.

A. Clarke AtwellBoard MemberFounded LUX Biosciences +1Daniel BradburyDirectorFounded Sensulin

Related companies · 6

Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
SolugenSolugen develops a biomanufacturing platform using fermentation and bioprocessing technology to produce specialty chemicals at scale. The company serves customers in energy, chemicals, and related industries with cost-effective alternatives to traditional petrochemical-based manufacturing.
NervGen PharmaNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
PepGenPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
UrogenUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.
AmgenAmgen is an independent biotechnology company that uses science and technology, including machine learning and human genetic data, to research and develop treatments for serious diseases such as cancer, heart disease, asthma, and osteoporosis. Its Danish operation, Amgen Danmark, focuses on improving health outcomes for patients and their families in Denmark.

Companies working in the same space as Synedgen.

Non-dilutive funding · 10 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
Department of DefenseDefense Health ProgramPhase II2020$1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$224.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$146.4K
Department of DefenseDefense Health ProgramPhase II2014$870.5K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$196.7K
Department of DefenseDefense Health ProgramPhase I2013$149.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2013$149.9K
National Institutes of Health (NIH)National Institutes of HealthPhase II2011$2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2010$99.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2009$99.7K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Funding and Support - Synedgensynedgen.com · Dec 2019Synedgen Awarded Funding to Advance Inflammatory Bowel Disease Treatments - Synedgensynedgen.com · Dec 2019

Frequently asked questions

What does Synedgen do?
Synedgen develops first-in-class glycomics-based regenerative therapeutics that repair mucosal injury and restore barrier function. Its lead asset, MIIST305, is an orally delivered therapeutic that repairs gastrointestinal mucosal injury and reduces inflammation.
Who founded Synedgen?
Synedgen was founded by Shenda Baker, William P. Wiesmann in 2009.
How much funding has Synedgen raised?
Synedgen has disclosed $20.4M raised across 7 rounds.
Where is Synedgen headquartered?
Synedgen is headquartered in Claremont, US.